reiterateAMGNfinnhub
Mizuho Reiterates Neutral Rating on Amgen Inc. (AMGN)
Mizuho reiterated its Neutral rating on Amgen Inc. (NASDAQ:AMGN) on August 18, 2026.
Read moreFeatured By
Real-time context
Upgrades, downgrades, initiations, and price-target changes.
Mizuho reiterated its Neutral rating on Amgen Inc. (NASDAQ:AMGN) on August 18, 2026.
Read moreGLJ Research reiterated its Sell rating on Tesla, Inc. (NASDAQ:TSLA) on August 18, 2026.
Read moreMorgan Stanley reiterated its Overweight rating on Chime Financial, Inc. Class A Common Stock (NASDAQ:CHYM) on August 18, 2026.
Read moreJefferies reiterated its Buy rating on EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) on August 17, 2026.
Read moreUBS reiterated its Neutral rating on Grocery Outlet Holding Corp. (NASDAQ:GO) on August 17, 2026.
Read moreChardan Capital reiterated its Buy rating on EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) on August 17, 2026.
Read moreJP Morgan analysts downgraded EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) from Overweight to Neutral on August 17, 2026.
Read moreBarclays reiterated its Overweight rating on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on August 17, 2026.
Read morePiper Sandler reiterated its Overweight rating on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on August 17, 2026.
Read moreMacquarie reiterated its Outperform rating on MGM Resorts International (NYSE:MGM) on August 17, 2026.
Read moreArgus Research reiterated its Buy rating on MGM Resorts International (NYSE:MGM) on August 17, 2026.
Read moreTruist Securities reiterated its Hold rating on Pinnacle West Capital Corporation (NYSE:PNW) on August 17, 2026.
Read moreGuggenheim reiterated its Buy rating on Formula One Group (NASDAQ:FWONK) on August 17, 2026.
Read moreStephens & Co. reiterated its Overweight rating on JBS N.V.
Read moreTruist Securities reiterated its Buy rating on Ameren Corporation (NYSE:AEE) on August 17, 2026.
Read moreWells Fargo analysts initiated coverage on Huntington Bancshares Incorporated (NASDAQ:HBANM) with a rating of Overweight on August 17, 2026.
Read moreHC Wainwright & Co. analysts downgraded EyePoint Pharmaceuticals, Inc.
Read moreChardan Capital analysts downgraded EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) from Buy to Neutral on August 18, 2026.
Read moreRBC Capital analysts downgraded EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) from Outperform to Sector Perform on August 18, 2026.
Read moreB of A Securities analysts initiated coverage on Kanzhun Limited (NASDAQ:BZ) with a rating of Neutral on August 18, 2026.
Read more